经口机器人术后阿片类药物使用与处方预测因素
该回顾性队列研究纳入138例经口机器人手术(TORS)治疗的口咽鳞状细胞癌(OPSCC)患者,量化术后12个月阿片类药物使用量(换算为吗啡毫克当量,MME)并分析处方预测因素。结果显示,辅助治疗显著增加MME用量和处方次数,并延长减量时间;辅助治疗和较高衰弱指数(mFI-5≥3)是阿片类药物处方的阳性预测因素。
要点
- TORS术后总MME平均为1395.7,76.4%患者接受≤3次处方。
- 辅助治疗显著增加MME和处方次数,并延长减量时间。
- 辅助治疗和mFI-5≥3是4-6个月及4-12个月阿片处方的预测因素。
核心结论
- 在TORS治疗的OPSCC中,单纯手术者的阿片类药物减量快于联合辅助治疗者。
- 辅助治疗和较高衰弱指数是阿片类药物处方的风险因素。
研究设计与样本
- 回顾性队列研究,纳入2016至2019年连续138例接受TORS的OPSCC患者。
- 通过处方记录与马萨诸塞州处方意识工具交叉核对,收集术后12个月阿片类药物使用量(标准化为MME)。
主要发现
- 138例中92.8%为HPV阳性;辅助治疗包括放疗(67.4%)和放化疗(6.5%)。
- 治疗开始后总MME平均为1395.7,76.4%患者接受≤3次处方。
- 辅助治疗显著增加MME(TORS+XRT:1646.2;TORS+cXRT:2385.0;TORS alone:554.7,P < .001)和12个月处方总数(TORS+XRT:3.2;TORS+cXRT:5.5;TORS alone:1.6,P < .001)。
- 辅助治疗延长减量时间:0-3个月总MME单纯手术 vs 辅助治疗为428.2 vs 845.5,4-6个月为46.8 vs 541.8,7-9个月为12.4 vs 178.6,10-12个月为11.0 vs 4.4(P < .001)。
- 4-6个月和4-12个月阿片处方的阳性预测因素包括辅助治疗(OR:5.56和4.51)和mFI-5评分≥3(OR:36.67和31.94);术后6、9、12个月仍使用阿片类药物的比例分别为15.7%、6.6%、4.1%。
关键数值与推荐
- 年龄<65、男性、超重BMI、较低衰弱、既往吸烟、HPV阳性、较高T分期和舌根亚部位与较高MME相关。
临床怎么用
- TORS术后应关注辅助治疗和衰弱指数较高的患者,这类患者阿片类药物减量更慢、处方风险更高。
局限性
- 回顾性研究,证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/HYPOTHESIS: Pain management following transoral robotic surgery (TORS) varies widely. We aim to quantify opioid usage following TORS for oropharyngeal squamous cell carcinoma (OPSCC) and identify prescribing predictors. STUDY DESIGN: Retrospective cohort study. METHODS: A consecutive series of 138 patients undergoing TORS for OPSCC were reviewed from 2016 to 2019. Opioid usage (standardized to morphine milligram equivalents [MME]) was gathered for 12 months post-surgery via prescribing record cross-check with the Massachusetts Prescription Awareness Tool. RESULTS: Of 138 OPSCC TORS patients, 92.8% were human papillomavirus (HPV) positive. Adjuvant therapy included radiation (XRT;67.4%) and chemoradiation (cXRT;6.5%). Total MME usage from start of treatment averaged 1395.7 MMEs with 76.4% receiving three prescriptions or less. Categorical analysis showed age <65, male sex, overweight BMI, lower frailty, former smokers, HPV+, higher T stage, and BOT subsite to be associated with increased MMEs. Adjuvant therapy significantly increased MMEs (TORS+XRT:1646.2; TORS+cXRT:2385.0; TORS alone:554.7 [P < .001]) and 12-month opioid prescription totals (TORS+XRT:3.2; TORS+cXRT:5.5; TORS alone:1.6 [P < .001]). Adjuvant therapy increased time to taper (total MME in TORS alone versus TORS+XRT/cXRT: 0 to 3 months:428.2 versus 845.5, 4 to 6 months:46.8 versus 541.8, 7 to 9 months:12.4 versus 178.6, 10 to 12 months:11.0 versus 4.4,[P < .001]). Positive predictors of opioid prescribing at the 4- to 6-month and 4- to 12-month intervals included adjuvant therapy (odds ratio [OR]:5.56 and 4.51) and mFI-5 score ≥3 (OR:36.67 and 31.94). Following TORS at 6-, 9-, and 12-month, 15.7%, 6.6%, and 4.1% were still using opioids. CONCLUSIONS: In OPSCC treated with TORS, opioid use tapers faster for surgery alone versus with adjuvant therapy. Opioid prescribing risks include adjuvant therapy and higher frailty index. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E1888-E1894, 2021.
引用
- Abt NB, Holcomb AJ, Feng AL, et al. Opioid Usage and Prescribing Predictors Following Transoral Robotic Surgery for Oropharyngeal Cancer. Laryngoscope. 2020. PMID: 33210756. doi:10.1002/lary.29276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。